Dilantin (Phenytoin) Nursing Considerations NCLEX Priority Sheet

NCLEX memory rule: nystagmus → ataxia → slurred speech → confusion → coma.

Other adverse effects: gingival hyperplasia, hirsutism, folate deficiency, osteomalacia/vitamin D issues with chronic use, and rash that may progress to Stevens-Johnson syndrome or TEN.

Trap: total phenytoin level is 14 mcg/mL, but albumin is 2.0 g/dL.

Answer: calculate corrected phenytoin before calling it therapeutic. Classic NCLEX formula: 14 / [(0.2 × 2.0) + 0.1] = 28 mcg/mL, which is toxic.

Phenytoin injection: the injection label describes normal-saline dilution and says to avoid dextrose-containing solutions because precipitation can occur. Product-specific administration still belongs to the active order, current label, and local protocol.

Fosphenytoin: a parenteral prodrug of phenytoin expressed in phenytoin equivalents (PE); it has its own product labeling and is not a substitute for checking the active formulation.

Formula note: real clinical interpretation should follow institutional lab/pharmacy guidance.

Start with the formulation, not just the drug name. The primary capsule label is for extended phenytoin sodium capsules taken by mouth. A separate label covers phenytoin sodium injection for IV or IM use, and another covers fosphenytoin injection, a parenteral prodrug whose amount and concentration are expressed in phenytoin equivalents (PE). On an exam, an oral capsule, an IV injection, and a fosphenytoin product are therefore three different label contexts—not interchangeable descriptions of one bedside procedure.

Study cue: when a stem changes the route, product, brand, salt form, or formulation, pause before carrying an oral fact into an IV question. The oral capsule label notes that changing between the free-acid and sodium-salt forms can change drug content and may require serum-level monitoring. That is an exam reason to identify the exact product first; it is not a dosing instruction.

Route boundary: this sheet summarizes recurring NCLEX concepts. The linked labels contain the actual product-specific administration language. In patient care, the current label, active order, pharmacy guidance, and local protocol control.

What the primary label supports: the extended-capsule and injection labels describe a commonly effective total phenytoin concentration of 10–20 mcg/mL and an unbound concentration of 1–2 mcg/mL. They also distinguish trough levels (taken just before a scheduled dose) from peak levels (used to assess the threshold for dose-related adverse effects). Those label concepts explain why NCLEX questions pair a number with timing and symptoms instead of treating one total level as a complete answer.

Albumin is the qualifier. Both labels state that the unbound fraction is more relevant when renal disease, hepatic disease, or hypoalbuminemia is present. The safe exam takeaway is to recognize that a total value can need context. The formula shown elsewhere on this priority sheet is a study convention; it does not replace a product label, lab method, prescriber, or pharmacist in actual care.

Do not turn a range into an order. A reported concentration, a symptom pattern, and the formulation all belong in the same question. This page deliberately does not provide a dose adjustment or an administration plan.

High-priority pattern recognition: the official labels list neurologic reactions such as nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. They also flag serious dermatologic reactions, DRESS/multiorgan hypersensitivity, hepatic injury, hematopoietic complications, and cardiac effects. For an NCLEX-style question, this supports sorting a new rash, fever, lymph-node swelling, facial swelling, jaundice, unusual bruising, or an escalating neurologic pattern above routine teaching points.

Why rash is not a minor finding: the label warns that severe cutaneous adverse reactions can occur and that early hypersensitivity manifestations may appear even before a rash is obvious. That makes the word “new” or “progressive” clinically important in a question stem. This is a recognition framework only; it is not a patient-specific triage protocol.

Withdrawal is another label-level warning. The oral and injection labels caution that abrupt withdrawal can precipitate seizures, including status epilepticus. On an exam, do not treat a stopped-anticonvulsant history as a neutral detail.

Interaction questions test process, not memorization alone. The extended-capsule label describes phenytoin as extensively protein bound, subject to saturable metabolism, and a potent inducer of hepatic drug-metabolizing enzymes. Its interaction tables are explicitly not exhaustive. A defensible study answer therefore recognizes the need to review the full medication, OTC, vitamin, herbal-product, and nutrition context against current product information rather than assuming a short list is complete.

Examples the label itself highlights: it notes that antacids may affect absorption, that enteral feeding preparations or related nutritional supplements have been associated with lower-than-expected phenytoin levels, and that warfarin responses may increase or decrease with co-administration. These are prompts to verify the active label and protocol—not instructions to alter a regimen.

Patient-counseling recognition point: the official capsule label includes good dental hygiene to minimize gingival-hyperplasia complications and cautions against changing or stopping therapy without clinician guidance. In this study sheet, treat those as label-supported teaching topics, not individualized advice.

Why is normal saline mentioned on this page? It comes from the phenytoin injection label, which describes saline dilution and warns against dextrose-containing solutions because of precipitation. It applies to that injectable product context, not as a universal instruction for every phenytoin formulation.

Why mention fosphenytoin separately? Its label identifies it as a parenteral prodrug of phenytoin and uses PE notation. The exam lesson is to read the exact product and units; bedside conversion or administration belongs to the current order, label, and protocol.

What is the answer when albumin is low? Recognize that the label makes the unbound fraction more relevant in hypoalbuminemia. Then keep the response inside the scope of the question—do not invent a dose change.

What should a real-care reader do with this sheet? Use it only to organize study concepts. For patient care, consult the current product label, the active order, and local protocol.

Primary labeling: Extended phenytoin sodium capsules prescribing information, Phenytoin sodium injection prescribing information, and Fosphenytoin sodium injection prescribing information (DailyMed).

Study-only boundary: This NCLEX summary is not an administration instruction. For patient care, use the current product label, the active order, and local protocol.